Satellos Bioscience Inc Com V.ICO

Primary Symbol: ICOTF

Healthcare Biotechnology

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...

GREY:ICOTF - Post by User

Satellos Bioscience Inc Com > high lights i copied ANNUAL INFORMATION FORM

<< Previous

Bullboard Posts

Next >>

Comment by Alba1314on Jul 24, 2018 10:04am

97 Views

Post# 28358224

RE:RE:RE:RE:RE:RE:high lights i copied ANNUAL INFORMATION FORM

Your spot on, there. Given that the total is milestone payments is 32M, I think its reasonable to exptect any milestone payment to have a positive impact on operations and more than likely the SP.

In a post last week, I wrote that looking at Cynapsus Therapeutics would give a good perspective on whats going on here. During their Phase III trials, a Japanese company came in and basically said "we've seen enough. Here's bags of money." That could happen with IMNP and part of that deal would probably be a lump sum to ICO for milestones.

If not, a series of payments to "keep the lights on" is still a good thing.

<< Previous

Bullboard Posts

Next >>

High Tide adds two stores to undervalued cannabis retail network